<DOC>
	<DOCNO>NCT03092037</DOCNO>
	<brief_summary>The propose study investigate relationship genetic variant serum contraceptive hormone level , specifically progestin etonogestrel . This study provide foundation future pharmacogenomic investigation commonly use contraceptive method higher failure rate .</brief_summary>
	<brief_title>Pharmacogenomics Contraception : Genetic Variants Etonogestrel Pharmacokinetics</brief_title>
	<detailed_description>Approximately 350 reproductive age woman ( 18-45 ) Etonogestrel ( ENG ) contraceptive implant place 1 year enrol . Participants undergo blood draw measurement ENG concentration ( serum ) genotyping ( whole blood ) complete questionnaire regard demographic contraceptive , gynecological , obstetrical history . The research investigator also consent participant use genetic sample clinical data future unspecified research . The serum sample de-identified ENG analysis , do use liquid chromatography-mass spectrometry method . Additional whole blood sample collect enrollment visit undergo DNA extraction -- research investigator select 120 genetic variant 10 target gene involve progestin metabolism , regulation , function .</detailed_description>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>woman reproductive age ( 1845 year ) ENG contraceptive implant place 1236 month Use medication supplement past four week could impact serum ENG level inhibition induction CYP enzymes ( specifically CYP3A4 ) Medical condition could impact baseline liver function ( e.g . hepatitis , cirrhosis ) Body mass index ( BMI ) less 18.5</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>